O	0	3	The
O	4	13	relevance
O	14	16	of
B-intervention	17	33	intraventricular
I-intervention	34	46	chemotherapy
O	47	50	for
O	51	65	leptomeningeal
O	66	76	metastasis
O	77	79	in
O	80	86	breast
O	87	93	cancer
O	93	94	:
O	95	96	a
O	97	107	randomised
O	108	113	study
O	113	114	.

O	115	117	To
O	118	124	assess
O	125	128	the
O	129	136	benefit
O	137	139	of
O	140	156	intraventricular
O	157	169	chemotherapy
O	169	170	,
B-eligibility	171	179	patients
I-eligibility	180	184	with
I-eligibility	185	199	leptomeningeal
I-eligibility	200	210	metastasis
I-eligibility	211	212	(
I-eligibility	212	214	LM
I-eligibility	214	215	)
I-eligibility	216	220	from
I-eligibility	221	227	breast
I-eligibility	228	234	cancer
O	235	239	were
O	240	250	randomised
O	251	253	to
O	254	263	treatment
O	264	273	including
O	274	290	intraventricular
O	291	292	(
O	292	294	IT
O	294	295	)
O	296	308	chemotherapy
O	309	310	(
O	310	311	n
O	311	312	=
B-intervention-participants	312	314	17
O	314	315	)
O	316	318	or
O	319	321	to
B-control	322	325	non
I-control	325	326	-
I-control	326	337	intrathecal
I-control	338	339	(
I-control	339	342	non
I-control	342	343	-
I-control	343	345	IT
I-control	345	346	)
I-control	347	356	treatment
O	357	358	(
O	358	359	n
O	359	360	=
B-control-participants	360	362	18
O	362	363	)
O	363	364	.

O	365	376	Appropriate
O	377	385	systemic
O	386	393	therapy
O	394	397	and
O	398	406	involved
O	407	412	field
O	413	422	radiation
O	423	430	therapy
O	431	432	(
O	432	434	RT
O	434	435	)
O	436	440	were
O	441	446	given
O	447	449	in
O	450	454	both
O	455	459	arms
O	459	460	.

O	461	470	Intention
O	470	471	-
O	471	473	to
O	473	474	-
O	474	479	treat
O	480	488	analysis
O	489	495	showed
B-outcome	496	508	neurological
I-outcome	509	520	improvement
I-outcome	521	523	or
I-outcome	524	537	stabilisation
O	538	540	in
B-iv-bin-percent	541	543	59
I-iv-bin-percent	543	544	%
O	545	547	of
O	548	551	the
O	552	554	IT
O	555	558	and
O	559	561	in
B-cv-bin-percent	562	564	67
I-cv-bin-percent	564	565	%
O	566	568	of
O	569	572	the
O	573	576	non
O	576	577	-
O	577	579	IT
O	580	585	group
O	585	586	,
O	587	591	with
B-outcome	592	598	median
I-outcome	599	603	time
I-outcome	604	606	to
I-outcome	607	618	progression
O	619	621	of
B-iv-cont-median	622	624	23
I-iv-cont-median	625	630	weeks
O	631	632	(
O	632	634	IT
O	634	635	)
O	636	639	and
B-cv-cont-median	640	642	24
I-cv-cont-median	643	648	weeks
O	649	650	(
O	650	653	non
O	653	654	-
O	654	656	IT
O	656	657	)
O	657	658	.

B-outcome	659	665	Median
I-outcome	666	674	survival
O	675	677	of
O	678	680	IT
O	681	689	patients
O	690	693	was
B-iv-cont-median	694	696	18
I-iv-cont-median	696	697	.
I-iv-cont-median	697	698	3
I-iv-cont-median	699	704	weeks
O	705	708	and
B-cv-cont-median	709	711	30
I-cv-cont-median	711	712	.
I-cv-cont-median	712	713	3
I-cv-cont-median	714	719	weeks
O	720	723	for
O	724	727	non
O	727	728	-
O	728	730	IT
O	731	739	patients
O	740	741	(
O	741	751	difference
O	752	754	12
O	754	755	.
O	755	756	9
O	757	762	weeks
O	762	763	;
O	764	766	95
O	766	767	%
O	768	778	Confidence
O	779	787	Interval
O	788	789	(
O	789	791	CI
O	791	792	)
O	793	794	-
O	794	795	5
O	795	796	.
O	796	797	5
O	798	800	to
O	801	802	+
O	802	804	34
O	804	805	.
O	805	806	3
O	807	812	weeks
O	812	813	;
O	814	815	P
O	815	816	=
O	816	817	0
O	817	818	.
O	818	820	32
O	820	821	)
O	821	822	.

B-outcome	823	835	Neurological
I-outcome	836	849	complications
O	850	852	of
O	853	862	treatment
O	863	871	occurred
O	872	874	in
B-iv-bin-percent	875	877	47
I-iv-bin-percent	877	878	%
O	879	880	(
O	880	882	IT
O	882	883	)
O	884	886	vs
B-cv-bin-percent	887	888	6
I-cv-bin-percent	888	889	%
O	890	891	(
O	891	894	non
O	894	895	-
O	895	897	IT
O	897	898	)
O	899	900	(
O	900	901	P
O	901	902	=
O	902	903	0
O	903	904	.
O	904	908	0072
O	908	909	)
O	909	910	.

O	911	913	In
O	914	924	conclusion
O	924	925	,
O	926	934	standard
O	935	943	systemic
O	944	956	chemotherapy
O	957	961	with
O	962	970	involved
O	971	976	field
O	977	979	RT
O	980	983	for
O	984	986	LM
O	987	991	from
O	992	998	breast
O	999	1005	cancer
O	1006	1008	is
O	1009	1017	feasible
O	1017	1018	.

O	1019	1027	Addition
O	1028	1030	of
O	1031	1047	intraventricular
O	1048	1060	chemotherapy
O	1061	1065	does
O	1066	1069	not
O	1070	1074	lead
O	1075	1077	to
O	1078	1086	survival
O	1087	1094	benefit
O	1095	1097	or
O	1098	1106	improved
O	1107	1119	neurological
O	1120	1128	response
O	1128	1129	,
O	1130	1133	and
O	1134	1136	is
O	1137	1147	associated
O	1148	1152	with
O	1153	1155	an
O	1156	1165	increased
O	1166	1170	risk
O	1171	1173	of
O	1174	1187	neurotoxicity
O	1187	1188	.
